vs
ABERCROMBIE & FITCH CO（ANF）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
ABERCROMBIE & FITCH CO的季度营收约是Revvity的1.7倍（$1.3B vs $772.1M），Revvity净利率更高（12.7% vs 8.8%，领先4.0%），ABERCROMBIE & FITCH CO同比增速更快（6.8% vs 5.9%），Revvity自由现金流更多（$161.8M vs $131.8M），过去两年Revvity的营收复合增速更高（9.0% vs -5.8%）
A&F（阿伯克龙比与菲奇）是1892年成立的美国生活方式零售品牌，主打面向20岁出头至45岁左右客群的潮流服饰，总部位于俄亥俄州新奥尔巴尼。旗下运营Abercrombie Kids、Your Personal Best、霍利斯特（Hollister Co.）、Gilly Hicks四个子品牌，全品牌直营门店超780家。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ANF vs RVTY — 直观对比
营收规模更大
ANF
是对方的1.7倍
$772.1M
营收增速更快
ANF
高出0.9%
5.9%
净利率更高
RVTY
高出4.0%
8.8%
自由现金流更多
RVTY
多$30.0M
$131.8M
两年增速更快
RVTY
近两年复合增速
-5.8%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $772.1M |
| 净利润 | $113.0M | $98.4M |
| 毛利率 | 62.5% | — |
| 营业利润率 | 12.0% | 14.5% |
| 净利率 | 8.8% | 12.7% |
| 营收同比 | 6.8% | 5.9% |
| 净利润同比 | -14.4% | 3.9% |
| 每股收益（稀释后） | $2.36 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANFRVTY
| Q4 25 | $1.3B | $772.1M | ||
| Q3 25 | $1.2B | $698.9M | ||
| Q2 25 | $1.1B | $720.3M | ||
| Q1 25 | $1.6B | $664.8M | ||
| Q4 24 | $1.2B | $729.4M | ||
| Q3 24 | $1.1B | $684.0M | ||
| Q2 24 | $1.0B | $691.7M | ||
| Q1 24 | $1.5B | $649.9M |
净利润ANFRVTY
| Q4 25 | $113.0M | $98.4M | ||
| Q3 25 | $141.4M | $46.7M | ||
| Q2 25 | $80.4M | $53.9M | ||
| Q1 25 | $187.2M | $42.2M | ||
| Q4 24 | $132.0M | $94.6M | ||
| Q3 24 | $133.2M | $94.4M | ||
| Q2 24 | $113.8M | $55.4M | ||
| Q1 24 | $158.4M | $26.0M |
毛利率ANFRVTY
| Q4 25 | 62.5% | — | ||
| Q3 25 | 62.6% | 53.6% | ||
| Q2 25 | 62.0% | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | 65.1% | — | ||
| Q3 24 | 64.9% | 56.3% | ||
| Q2 24 | 66.4% | 55.7% | ||
| Q1 24 | 62.9% | 54.6% |
营业利润率ANFRVTY
| Q4 25 | 12.0% | 14.5% | ||
| Q3 25 | 17.1% | 11.7% | ||
| Q2 25 | 9.3% | 12.6% | ||
| Q1 25 | 16.2% | 10.9% | ||
| Q4 24 | 14.8% | 16.3% | ||
| Q3 24 | 15.5% | 14.3% | ||
| Q2 24 | 12.7% | 12.4% | ||
| Q1 24 | 15.3% | 6.8% |
净利率ANFRVTY
| Q4 25 | 8.8% | 12.7% | ||
| Q3 25 | 11.7% | 6.7% | ||
| Q2 25 | 7.3% | 7.5% | ||
| Q1 25 | 11.8% | 6.4% | ||
| Q4 24 | 10.9% | 13.0% | ||
| Q3 24 | 11.7% | 13.8% | ||
| Q2 24 | 11.2% | 8.0% | ||
| Q1 24 | 10.9% | 4.0% |
每股收益（稀释后）ANFRVTY
| Q4 25 | $2.36 | $0.86 | ||
| Q3 25 | $2.91 | $0.40 | ||
| Q2 25 | $1.59 | $0.46 | ||
| Q1 25 | $3.55 | $0.35 | ||
| Q4 24 | $2.50 | $0.77 | ||
| Q3 24 | $2.50 | $0.77 | ||
| Q2 24 | $2.14 | $0.45 | ||
| Q1 24 | $2.97 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $631.0M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.3B | $7.3B |
| 总资产 | $3.5B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANFRVTY
| Q4 25 | $631.0M | $919.9M | ||
| Q3 25 | $603.5M | $931.4M | ||
| Q2 25 | $607.6M | $991.8M | ||
| Q1 25 | $888.9M | $1.1B | ||
| Q4 24 | $738.9M | $1.2B | ||
| Q3 24 | $738.4M | $1.2B | ||
| Q2 24 | $864.2M | $2.0B | ||
| Q1 24 | $900.9M | $1.7B |
股东权益ANFRVTY
| Q4 25 | $1.3B | $7.3B | ||
| Q3 25 | $1.3B | $7.4B | ||
| Q2 25 | $1.2B | $7.6B | ||
| Q1 25 | $1.3B | $7.6B | ||
| Q4 24 | $1.2B | $7.7B | ||
| Q3 24 | $1.2B | $7.9B | ||
| Q2 24 | $1.1B | $7.9B | ||
| Q1 24 | $1.0B | $7.8B |
总资产ANFRVTY
| Q4 25 | $3.5B | $12.2B | ||
| Q3 25 | $3.3B | $12.1B | ||
| Q2 25 | $3.1B | $12.4B | ||
| Q1 25 | $3.3B | $12.4B | ||
| Q4 24 | $3.3B | $12.4B | ||
| Q3 24 | $3.0B | $12.8B | ||
| Q2 24 | $3.0B | $13.4B | ||
| Q1 24 | $3.0B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $200.1M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $131.8M | $161.8M |
| 自由现金流率自由现金流/营收 | 10.2% | 21.0% |
| 资本支出强度资本支出/营收 | 5.3% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.77× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $384.5M | $509.4M |
8季度趋势，按日历期对齐
经营现金流ANFRVTY
| Q4 25 | $200.1M | $182.0M | ||
| Q3 25 | $116.9M | $138.5M | ||
| Q2 25 | $-4.0M | $134.3M | ||
| Q1 25 | $307.6M | $128.2M | ||
| Q4 24 | $142.6M | $174.2M | ||
| Q3 24 | $165.1M | $147.9M | ||
| Q2 24 | $95.0M | $158.6M | ||
| Q1 24 | $303.3M | $147.6M |
自由现金流ANFRVTY
| Q4 25 | $131.8M | $161.8M | ||
| Q3 25 | $50.7M | $120.0M | ||
| Q2 25 | $-54.8M | $115.5M | ||
| Q1 25 | $256.8M | $112.2M | ||
| Q4 24 | $92.2M | $149.8M | ||
| Q3 24 | $122.3M | $125.6M | ||
| Q2 24 | $56.1M | $136.6M | ||
| Q1 24 | $274.1M | $129.7M |
自由现金流率ANFRVTY
| Q4 25 | 10.2% | 21.0% | ||
| Q3 25 | 4.2% | 17.2% | ||
| Q2 25 | -5.0% | 16.0% | ||
| Q1 25 | 16.2% | 16.9% | ||
| Q4 24 | 7.6% | 20.5% | ||
| Q3 24 | 10.8% | 18.4% | ||
| Q2 24 | 5.5% | 19.7% | ||
| Q1 24 | 18.9% | 20.0% |
资本支出强度ANFRVTY
| Q4 25 | 5.3% | 2.6% | ||
| Q3 25 | 5.5% | 2.6% | ||
| Q2 25 | 4.6% | 2.6% | ||
| Q1 25 | 3.2% | 2.4% | ||
| Q4 24 | 4.2% | 3.4% | ||
| Q3 24 | 3.8% | 3.3% | ||
| Q2 24 | 3.8% | 3.2% | ||
| Q1 24 | 2.0% | 2.7% |
现金转化率ANFRVTY
| Q4 25 | 1.77× | 1.85× | ||
| Q3 25 | 0.83× | 2.97× | ||
| Q2 25 | -0.05× | 2.49× | ||
| Q1 25 | 1.64× | 3.03× | ||
| Q4 24 | 1.08× | 1.84× | ||
| Q3 24 | 1.24× | 1.57× | ||
| Q2 24 | 0.83× | 2.87× | ||
| Q1 24 | 1.91× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANF
| Hollister | $673.3M | 52% |
| Abercrombie | $617.3M | 48% |
| Gift Card | $25.7M | 2% |
| Royalty | $19.5M | 2% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
